Unlock instant, AI-driven research and patent intelligence for your innovation.

Hydroxamic acid compound used as histone deacetylase inhibitor and application thereof

A compound and pharmaceutical technology, applied in the field of hydroxamic acid-type histone deacetylase inhibitors, can solve the problems of high toxicity, inaccurate curative effect, few types of deacetylase inhibitors, etc.

Inactive Publication Date: 2010-02-17
苏州东南药业股份有限公司
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0023] The purpose of the present invention is to provide a novel histone deacetylase inhibitor, which solves the problems of less types of histone deacetylase inhibitors, inaccurate curative effect and high toxicity in the prior art for the treatment of tumors and leukemia.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hydroxamic acid compound used as histone deacetylase inhibitor and application thereof
  • Hydroxamic acid compound used as histone deacetylase inhibitor and application thereof
  • Hydroxamic acid compound used as histone deacetylase inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1 Preparation of 7-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanoic acid methyl ester

[0070]

[0071] Aniline oxime (5g, 36.7mmol) was dissolved in 15mL of pyridine, and 8-chloro-8-oxooctanoic acid methyl ester (9.11g, 44.1mmol) was added dropwise within 30min at room temperature, and the reflux reaction was completed. After the reaction of aniline oxime is complete, cool to room temperature, add ethyl acetate and water for distribution, and wash the organic layer with 2M aqueous hydrochloric acid solution, saturated sodium bicarbonate solution and saturated brine successively, dry the organic layer with magnesium sulfate, and pass through a silica gel column layer. A colorless oily liquid was obtained by analysis. Yield 65%. Heptanoic acid methyl esters of other substituents were synthesized in the same way, and the yield was 52-70%. 1 H-NMR (500Hz, CDCl 3 )δ: 8.06-8.08 (m, 2H), 7.28-7.49 (m, 3H), 3.66 (s, CO 2 CH 3 , 3H), 2.94(t, J=7.5Hz, het-CH 2 CH 2 , 2...

Embodiment 2

[0072] Example 2 Preparation of 7-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanoic acid

[0073]

[0074] Dissolve 15 mmol of methyl 7-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanoate in 30 mL of tetrahydrofuran, add 30 mL of 0.6 M lithium hydroxide aqueous solution, and stir overnight at room temperature. Add 150 mL of water, extract with ethyl acetate, discard the organic layer, acidify the lower aqueous solution to a pH equal to 3, extract with ethyl acetate (3×50 mL), combine the organic layers, wash with saturated brine, dry over anhydrous magnesium sulfate, and evaporate the solvent under reduced pressure. That is, 7-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanoic acid was obtained with a yield of 70-95%. Mp: 100-101°C.

Embodiment 3

[0075] Example 3 Preparation of N-hydroxyl-7-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanamide (compound 1)

[0076]

[0077] At 0°C, a tetrahydrofuran solution of ethyl chloroformate (1.3g, 12mmol) was added dropwise to 7-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanoic acid (2.74g, 10mmol) and N-methylmorpholine (1.3g, 13mmol) in THF solution, the mixture was reacted for 30min. The generated salt was removed by filtration, and the filtrate was added dropwise to a methanol solution of hydroxylamine, and the reaction mixture was stirred at room temperature for 30 min. The solvent was distilled off, ethyl acetate and saturated ammonium chloride solution were added for partitioning, the organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off to obtain 2.31 g of white solid with a yield of 80%. Mp: 84-86°C. 1 H-NMR (300Hz, DMSO-d6) δ: 10.36(s, -NHOH), 8.66(s, -NHOH), 7.99-8.02(m, 2H), 7.56-7.58(m, 3H), 2.99(t, J = 7.45Hz, CH 2 CH 2 CO 2 NHOH, 2H), 1....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound in the formula (I) or pharmaceutically acceptable salt thereof. Ar is aryl or heterocyclic group and is substituted by optional one or more of the following groups:C1-8 alkyl, C1-8 alkoxy, halogen, nitryl, C1-8 aminoalkyl, C1-8 alkyl amino group, C1-8 thio-alkyl, C1-8 halogenated alkyl, C1-8 halogenated alkoxy, C1-8 ester group, phenyl or heterocyclic group. n is an integer between 0 and 8. The drugs prepared by the compound can be used for treating solid tumors or leukemia correlating with cell differentiation or proliferation.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and specifically relates to a class of hydroxamic acid histone deacetylase inhibitors and applications thereof. Background technique [0002] The formation of many diseases, including tumors, is a rather complex process, involving how various genes respond to changes in the internal and external environment, thereby achieving the regulation of expression in time and space. A frontier field emerging in genetics in recent years - epigenetics (Epigenetics) provides new ideas for answering these questions. The molecular basis of epigenetics mainly involves two aspects: one is the methylation modification of DNA, and the other is the acetylation modification of chromatin histones. In addition to the DNA sequence as the genetic code, epigenetic mechanisms are the most fundamental regulators of gene expression and subsequent protein synthesis. In eukaryotic cells, in the G0 phase, DNA is tightly pack...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D271/06C07D413/04A61K31/4245A61K31/4439A61P35/00A61P35/02
Inventor 吉民魏红涛吴晓晴
Owner 苏州东南药业股份有限公司